Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $5.43 Consensus Target Price from Brokerages
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have earned a consensus recommendation of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have earned a consensus recommendation of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price […]
